Table 3 Factors associated with overweight and obesity in multivariable analyses (multinomial logistic regression, ANRS CO22 Hepather cohort, N = 6049)

 Male (ref.)

1

1

 Female

0.46 [0.41–0.53]

< 10⁻³

0.86 [0.73–1.03]

0.094

Age at baseline (years)

1.01 [1.00–1.02]

0.002

0.99 [0.98–1.00]

0.062

Place of birth

< 10⁻³

< 10⁻³

 France (ref.)

1

1

 Europe + North America + Latin America + Australia

1.10 [0.88–1.37]

0.397

1.39 [1.04–1.84]

0.024

 North Africa + Middle East

1.20 [0.97–1.48]

0.093

1.67 [1.28–2.18]

< 10⁻³

 Sub-Saharan Africa + the Caribbean

1.75 [1.35–2.28]

< 10⁻³

2.61 [1.93–3.53]

< 10⁻³

 Asia

0.76 [0.53–1.08]

0.122

1.14 [0.74–1.75]

0.550

Cannabis use

< 10⁻³

< 10⁻³

 Never (ref.)

1

1

 Former

0.78 [0.66–0.92]

0.003

0.58 [0.46–0.74]

< 10⁻³

 Current

0.47 [0.38–0.59]

< 10⁻³

0.27 [0.19–0.39]

< 10⁻³

Tobacco smoking

0.004

< 10⁻³

 Never (ref.)

1

1

 Former

1.02 [0.87–1.20]

0.773

1.38 [1.12–1.69]

0.002

 Current

0.79 [0.66–0.94]

0.007

0.82 [0.65–1.03]

0.093

 No (ref.)

1

1

 Yes

1.21 [1.05–1.40]

0.008

1.34 [1.11–1.62]

0.003

 < upper secondary school certificate (ref.)

1

1

 > upper secondary school certificate

0.81 [0.72–0.92]

0.001

0.61 [0.52–0.73]

< 10⁻³

 No (ref.)

1

1

 Yes

1.02 [0.89–1.17]

0.769

0.69 [0.57–0.83]

< 10⁻³

Time since HCV diagnosis (years)

0.99 [0.98–1.00]

0.033

0.99 [0.98–1.00]

0.052

HCV treatment history

< 10⁻³

< 10⁻³

 None (ref.)

1

1

 Interferon-based

1.33 [1.16–1.51]

< 10⁻³

1.46 [1.22–1.74]

< 10⁻³

 1^st or 2^nd generation DAA

1.60 [1.30–1.96]

< 10⁻³

2.13 [1.64–2.76]

< 10⁻³

 Other

1.20 [0.83–1.72]

0.338

1.02 [0.60–1.73]

0.948